Mixed clinical results led shares of Arvinas Inc. (NASDAQ:ARVN) to close March 11 at $8.30, down $9.26, or 52%, after the company and Pfizer Inc. disclosed results from the phase III Veritac-2 study ...

Sooma Oy secured U.S. FDA investigational device exemption approval to initiate a pivotal study of its transcranial direct ...

Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s rocatinlimab, a T-cell rebalancing therapy, in moderate to severe atopic dermatitis.

While the U.S. has historically led the global pharmaceutical industry by pursuing both continual innovation and high quality, those strengths could become areas of weakness in times of political ...

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full day of the conference, reports from the ...

Medtronic plc reported results from a registry highlighting the effectiveness of the Prevail paclitaxel-coated balloon. The ...

Calidi Biotherapeutics Inc. has released promising preclinical results for its systemic Rtnova platform showing its ability ...

Researchers from Diosynvax Ltd. presented data from a study that aimed to evaluate the efficacy of a pan-H5 vaccine designed ...

In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S.

Positive 16-week extension data from Cervomed Inc.’s phase IIb in dementia with Lewy bodies followed a failure from December. New results from the Rewind-LB trial testing neflamapimod, a ...

Sarcomas are generally classified into soft tissue sarcomas, such as fibrosarcoma, and bone sarcomas such as chondrosarcoma, which are rare cancers in adults accounting for about 1% of all cancer ...

Atopic dermatitis (AD) is a chronic, inflammatory skin condition driven by complex immune mechanisms involving T cells. In the context of AD, OX40, a costimulatory receptor present on activated T ...